Glomerular enlargement in the progression of mesangial proliferative glomerulonephritis. 1998

S Daimon, and I Koni
Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan.

A close association between glomerular hypertrophy and subsequent sclerosis had been demonstrated in diverse animal and human studies. We investigated the relationship between the glomerular volume and glomerular constituents (mesangial matrix, mesangial cells and capillary lumens) in human mesangial proliferative glomerulonephritis (GN). The data were obtained from glomeruli in the specimens of 23 patients undergoing repeat renal biopsies. Glomerular volume and glomerular constituents of each patient were obtained by averaging those of all glomeruli in each specimen. The interval from the first biopsy to the second was 51.2 +/- 6.8 months and the number of glomeruli included in each specimen was 16 +/- 1. Between glomerular volume and fractional mesangial volume, three patterns were recognized. In 8 of 23 patients glomerular volume and fractional mesangial volume were increased in the second biopsy (Group A). In 12 of 23 patients glomerular volume was decreased and fractional mesangial volume increased in the second biopsy (Group B), and in 3 of 23 patients glomerular volume was increased and fractional mesangial volume decreased in the second biopsy (Group C). One patient who underwent renal biopsy three times shifted from Group A to Group B in the course of mesangial proliferative GN. At the final follow-up, 4 of 12 patients in Group B required hemodialysis in contrast to none of 8 patients in Group A. Between glomerular volume and fractional mesangial volume, a positive and inverse relation existed, and we considered that in the course of mesangial proliferative GN, initially, glomerular size increases and thereafter decreases progressively. With glomerular enlargement, mesangial matrix expansion, glomerular capillary enlargement and relative decrease of the number of capillary lumen profiles and mesangial cells per glomerulus to increased glomerular volume were recognized. We concluded that these histological changes play a role in the progression of mesangial proliferative GN in humans as has been speculated in animal models of renal ablation.

UI MeSH Term Description Entries
D007678 Kidney Glomerulus A cluster of convoluted capillaries beginning at each nephric tubule in the kidney and held together by connective tissue. Glomerulus, Kidney
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001706 Biopsy Removal and pathologic examination of specimens from the living body. Biopsies
D015432 Glomerulonephritis, Membranoproliferative Chronic glomerulonephritis characterized histologically by proliferation of MESANGIAL CELLS, increase in the MESANGIAL EXTRACELLULAR MATRIX, and a thickening of the glomerular capillary walls. This may appear as a primary disorder or secondary to other diseases including infections and autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Various subtypes are classified by their abnormal ultrastructures and immune deposits. Hypocomplementemia is a characteristic feature of all types of MPGN. C3G Complement 3 Glomerulopathy,Complement 3 Glomerulopathies,Complement 3 Glomerulopathy,Glomerulonephritis, Mesangiocapillary,MPGN Membranoproliferative Glomerulonephritis,Membranoproliferative Glomerulonephritis,Mesangiocapillary Glomerulonephritis,DDD MPGNII,Dense Deposit Disease,Glomerulonephritis, Hypocomplementemic,MPGNII,Membranoproliferative Glomerulonephritis Type II,Membranoproliferative Glomerulonephritis, Type I,Membranoproliferative Glomerulonephritis, Type II,Membranoproliferative Glomerulonephritis, Type III,Mesangiocapillary Glomerulonephritis, Type I,Mesangiocapillary Glomerulonephritis, Type II,Subendothelial Membranoproliferative Glomerulonephritis,Type II MPGN,DDD MPGNIIs,Glomerulonephritides, MPGN Membranoproliferative,Glomerulonephritides, Membranoproliferative,Glomerulonephritis, MPGN Membranoproliferative,Glomerulopathies, Complement 3,Glomerulopathy, Complement 3,Hypocomplementemic Glomerulonephritides,Hypocomplementemic Glomerulonephritis,MPGN Membranoproliferative Glomerulonephritides,MPGN, Type II,MPGNII, DDD,MPGNIIs,Membranoproliferative Glomerulonephritides,Membranoproliferative Glomerulonephritides, MPGN,Membranoproliferative Glomerulonephritis, MPGN,Membranoproliferative Glomerulonephritis, Subendothelial,Mesangiocapillary Glomerulonephritides,Type II MPGNs
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

S Daimon, and I Koni
January 1997, Ryoikibetsu shokogun shirizu,
S Daimon, and I Koni
July 1978, Laboratory investigation; a journal of technical methods and pathology,
S Daimon, and I Koni
October 2004, Nihon rinsho. Japanese journal of clinical medicine,
S Daimon, and I Koni
January 1993, Kidney international. Supplement,
S Daimon, and I Koni
June 1982, Klinicheskaia meditsina,
S Daimon, and I Koni
May 1996, Biochemical and biophysical research communications,
S Daimon, and I Koni
December 1982, The International journal of pediatric nephrology,
S Daimon, and I Koni
January 1980, Minerva nefrologica,
Copied contents to your clipboard!